Efficacy and Safety of HA35 Gel for Mild Gingival Recession and Periodontal Inflammation

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorNakhia Impex LLC

About this trial

This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of topical 10% high-concentration 35 kDa hyaluronan (HA35) gel in subjects with mild gingival recession and chronic periodontal inflammation. Eligible participants will apply the HA35 gel topically to the gingival and tooth surfaces twice daily for 42 consecutive days. The primary objectives are to assess changes in gingival recession, chronic gingival or radicular pain, gingival redness and swelling, and brushing-induced bleeding. Safety and local oral tolerability will be evaluated throughout the treatment period. This is a minimal-risk, non-pharmacological, non-invasive oral care intervention.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 18-60 years, male or female

Clinically diagnosed with mild gingival recession (Miller Class I or II)

Chronic gingival pain, redness, swelling, or brushing-induced bleeding

Ability to complete self-assessments and comply with 42-day intervention

Disqualifiers

Severe periodontitis, tooth mobility, or alveolar bone loss

Uncontrolled diabetes or immune dysfunction

Use of prescription periodontal medications within 2 weeks

Known hypersensitivity to hyaluronan or gel components

Trial design

Design model

Single group

Treatments tested in this trial

  • 10% High-Concentration 35 kDa Hyaluronan (HA35) Gingival Topical Gel

    Device

    Topical oral gel containing 10% high-concentration 35 kDa hyaluronan fragment. Applied topically to gingival and tooth surfaces to improve mild gingival recession, reduce periodontal inflammation, relieve gingival pain, and decrease brushing-induced bleeding.

Treatment groups

30 Participants
are divided into 1 treatment group
Group A: HA35 Topical Gingival Gel GroupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Change in Gingival Recession Depth (mm)

Change in gingival recession depth, measured in millimeters (mm) using a calibrated periodontal probe. Baseline measurement is the distance from the cementoenamel junction (CEJ) to the gingival margin.

Time frame
Baseline to Day 42

Secondary outcomes

1

Change in Chronic Gingival/Radicular Pain Intensity (0-10 NRS)

Change in chronic gingival or radicular pain intensity, assessed using a 0-10 Numeric Rating Scale (NRS), where 0 = no pain and 10 = worst imaginable pain.

Time frame
Baseline to Day 42
2

Change in Gingival Itching/Discomfort Intensity (0-10 NRS)

Change in gingival itching or discomfort intensity, assessed using a 0-10 Numeric Rating Scale (NRS), where 0 = no discomfort and 10 = maximum discomfort.

Time frame
Baseline to 30 seconds after first application
3

Change in Gingival Redness and Swelling Severity (0-10 Scale)

Change in gingival redness and swelling severity, assessed using a 0-10 ordinal scale, where 0 = normal gingiva and 10 = severe redness and swelling.

Time frame
Baseline to Day 4
4

Resolution Rate of Brushing-Induced Gingival Bleeding

Proportion of participants with complete resolution of brushing-induced gingival bleeding, defined as no bleeding observed during gentle tooth brushing.

Time frame
Baseline to Day 2

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: